The Continuous Performance Test (CPT) study: OROS-methylphenidate efficacy on objective measures

Efficacy of OROS-methylphenidate on specific executive functioning deficits in adults with Attention deficit hyperactivity disorder (ADHD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN52392534

Enrollment

Registered

2013-07-02

Start date

2007-11-01

Completion date

Unknown

Last updated

2019-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit/Hyperactivity Disorder Mental and Behavioural Disorders Disturbance of activity and attention

Interventions

The total duration of the study period was 6 weeks. The first week was the baseline measurement (medication-naïve), the second and third week constituted the first treatment period, the fourth week wa

medication-naïve), lead-in dose of 36 mg placebo medication (week 2), test dose of 72 mg placebo medication (week 3), wash-out week (week 4), lead-in dose of 36 mg OROS-methylphenidate (week 5), and t

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Between 18-55 years of age. The participants are of either sex. We included 22 adults with the combined subtype of ADHD, of which 17 were male and 5 were female. 2. Diagnosis of ADHD, combined subtype

Exclusion criteria

Exclusion criteria: 1. Having severe comorbid psychiatric disorders at time of the study screening (as measured by the Structured Clinical Interview for DSM disorders; SCID) 2. Receiving treatment with stimulants, antipsychotics, clonidine, benzodiazepines, or beta-blockers <1 month before study participation 3. Having any cognitive disorder like dementia or amnesic disorder 4. Mental retardation 5. Being pregnant or nursing

Design outcomes

Primary

Measure	Time frame
Objective efficacy of medication on five parameters of the Conner?s Continuous Performance Test (C-CPT) and Test of Variables of Attention (TOVA): Hit Reaction Time (HRT), Reaction Time Variability (RTV), Omission Errors (OE), Commission Errors (CE), and D-Prime (DP). The primary outcomes were measured at baseline, after using 72mg of placebo medication, and after using 72mg of OROS-methylphenidate, that is, at the end of week 1, week 3 and week 6.	—

Measure

Time frame

Objective efficacy of medication on five parameters of the Conner?s Continuous Performance Test (C-CPT) and Test of Variables of Attention (TOVA): Hit Reaction Time (HRT), Reaction Time Variability (RTV), Omission Errors (OE), Commission Errors (CE), and D-Prime (DP). The primary outcomes were measured at baseline, after using 72mg of placebo medication, and after using 72mg of OROS-methylphenidate, that is, at the end of week 1, week 3 and week 6.

—

Secondary

Measure	Time frame
1. Subjective efficacy as measured by the number of ADHD symptoms using the ADHD-Rating scale 2. Adherence to medication using the Adherence Questionnaire 3. Side effects of medication using the Side Effects Rating Scale The secondary outcomes were tested every week in order to monitor the well-being and adherence of the participants, but only considered for analyses in week 1, week 3 and week 6 (i.e., at baseline, after using 72mg of placebo medication, and after using 72mg of OROS-methylphenidate).	—

Measure

Time frame

1. Subjective efficacy as measured by the number of ADHD symptoms using the ADHD-Rating scale 2. Adherence to medication using the Adherence Questionnaire 3. Side effects of medication using the Side Effects Rating Scale The secondary outcomes were tested every week in order to monitor the well-being and adherence of the participants, but only considered for analyses in week 1, week 3 and week 6 (i.e., at baseline, after using 72mg of placebo medication, and after using 72mg of OROS-methylphenidate).

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026